RT Generic
T1 Pharmacological interventions for acute hepatitis B infection: an attempted networkmeta-analysis
A1 Mantzoukis, Konstantinos
A1 Rodriguez-Peralvarez, Manuel
A1 Buzzetti, Elena
A1 Thorburn, Douglas
A1 Davidson, Brian R.
A1 Tsochatzis, Emmanuel
A1 Gurusamy, Kurinchi Selvan
K1 Trial sequential-analysis
K1 Placebo-controlled trial
K1 Acute viral-hepatitis
K1 Double-blind
K1 Design characteristics
AB BackgroundInfection with hepatitis B virus (HBV) can be symptomatic or asymptomatic. Apart from chronic HBV infection, the complications related to acute HBV infection are severe acute viral hepatitis and fulminant hepatitis characterised by liver failure. The optimal pharmacological treatment of acute HBV infection remains controversial.ObjectivesTo assess the benefits and harms of pharmacological interventions in the treatment of acute HBV infection through a network metaanalysis and to generate rankings of the available treatments according to their safety and efficacy. As it was not possible to assess whether the potential effect modifiers were similar across different comparisons, we did not perform the network meta-analysis, and instead, assessed the benefits and harms of different interventions using standard Cochrane methodological procedures.Search methodsWe searchedCENTRAL, MEDLINE, Embase, ScienceCitation IndexExpanded, WHOInternationalClinicalTrialsRegistry Platform, and randomised clinical trials (RCTs) registers to August 2016 to identify RCTs on pharmacological interventions for acute HBV infection.Selection criteriaRCTs, irrespective of language, blinding, or publication status in participants with acuteHBVinfection. We excluded trials if participants had previously undergone liver transplantation and had other coexisting viral diseases such as hepatitis C virus and HIV. We considered any of the various pharmacological interventions compared with each other or with placebo, or no intervention.Data collection and analysisWe calculated the odds ratio (OR) and rate ratio with 95% confidence intervals (CI) using both fixed-effect and random-effects models based on available-participant analysis with Review Manager 5. We assessed risk of bias, controlled risk of random errors with Trial Sequential Analysis, and assessed the quality of the evidence using GRADE.
PB Wiley
PB John Wiley & Sons
SN 1469-493X
YR 2017
FD 2017-01-01
LK http://hdl.handle.net/10668/18602
UL http://hdl.handle.net/10668/18602
LA en
NO Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, et al. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017 Mar 21;3(3):CD011645
DS RISalud
RD Apr 15, 2025